Last reviewed · How we verify
ATR-002 MEK Inhibitor
MEK inhibitor
MEK inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | ATR-002 MEK Inhibitor |
|---|---|
| Also known as | PD01842649 |
| Sponsor | Atriva Therapeutics GmbH |
| Drug class | MEK inhibitor |
| Target | MEK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Inhibits the activity of MEK enzymes, which are involved in the MAPK/ERK signaling pathway.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib (PHASE1)
- Phase 1 Study of ATR-002 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATR-002 MEK Inhibitor CI brief — competitive landscape report
- ATR-002 MEK Inhibitor updates RSS · CI watch RSS
- Atriva Therapeutics GmbH portfolio CI